Therapeutic Profile of Stroke Patients Managed with Neuroprotective Regimens

13^th International Conference on Stroke, Neurology and Cerebrovascular Diseases

June 20-21, 2022 | Webinar

J. Khan MD, MPH ,Ishaq Khan MD. MSPH.FACP. PhD ,M. Tanveer MBBS, DPH

Mediks International Hospital? Research Center, Pakistan

Scientific Tracks Abstracts: J Neurol Disord

Abstract :

Development of safe and affective neuroprotective drugs for stroke management has been a medical subject for a number of years. Several clinical trials were withdrawn in vainness due to lack of optimum Therapeutic outcomes. Nonetheless, recently a number of encouraging facts has highly supported demanding enthusiasm linked to management of stroke. Neuroprotective have worked in growing window time period of suitability fostering endovascular thrombectomy. Stroke is a notable cause of morbidity and mortality around the globe. Larger understanding of the pathophysiology of neuronal damage in ischemic stroke has created interest in neuroprotection as a managing strategy. Neuroprotection is an increasingly recognized management strategy in ischemic stroke that promises to involvement clinicians in reducing stroke mortality rates and improving the quality of life of survivors.

Biography :

Ishaq Khan has completed his MSPH & PhD from Walden University Minnesota Minneapolis USA in 2009 &2012.